Table 5.

Exposure to study treatments: safety populationa

ParameterCohort 1/expansion (n = 31)Cohort 2a (n = 3)All patients (N = 34)
Exposure to pralatrexate
Median number of cycles (range)6 (1–33)5 (2–9)5.5 (1–33)
Median number of doses (range)15 (2–84)10 (2–24)14 (2–84)
Median total dose, mg/m2 (range)227.8 (30–1,238)113.4 (30–360)205.5 (30–1,238)
Dose reductions, n (%)8 (26)1 (33)9 (26)
Exposure to bexarotene
Median number of cycles (range)6 (1–33)5 (2–9)6 (1–33)
Median duration, days (range)168.5 (15–916)127 (30–240)168 (15–916)
Dose reductions, n (%)9 (29)1 (33)10 (29)
  • aIncluded all patients who received at least 1 dose of pralatrexate or bexarotene.